Terms: = Ovarian cancer AND DNMT3A, Q9Y6K1, 1788, ENSG00000119772, DNMT3A2, M_HsaIIIA
48 results:
1. Evolutionary mode and timing of dissemination of high-grade serous carcinomas.
Sveen A; Johannessen B; Klokkerud SM; Kraggerud SM; Meza-Zepeda LA; Bjørnslett M; Bischof K; Myklebost O; Taskén K; Skotheim RI; Dørum A; Davidson B; Lothe RA
JCI Insight; 2024 Jan; 9(3):. PubMed ID: 38175731
[TBL] [Abstract] [Full Text] [Related]
2. Enhancing wound healing and overcoming cisplatin resistance in ovarian cancer.
Zhang Q; Guo F; Liu H; Hong L
Int Wound J; 2024 Apr; 21(4):e14569. PubMed ID: 38158767
[TBL] [Abstract] [Full Text] [Related]
3. miR-29c-3p acts as a tumor promoter by regulating β-catenin signaling through suppressing dnmt3a, TET1 and HBP1 in ovarian carcinoma.
Zhao H; Feng L; Cheng R; Wu M; Bai X; Fan L; Liu Y
Cell Signal; 2024 Jan; 113():110936. PubMed ID: 37925048
[TBL] [Abstract] [Full Text] [Related]
4. In Silico Identification of a BRCA1:miR-29:DNMT3 Axis Involved in the Control of Hormone Receptors in BRCA1-Associated Breast cancers.
Santarosa M; Baldazzi D; Armellin M; Maestro R
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373065
[TBL] [Abstract] [Full Text] [Related]
5. LncRNA KCNQ1OT1 promotes the metastasis of ovarian cancer by increasing the methylation of EIF2B5 promoter.
He SL; Chen YL; Chen QH; Tian Q; Yi SJ
Mol Med; 2022 Sep; 28(1):112. PubMed ID: 36100884
[TBL] [Abstract] [Full Text] [Related]
6. Downregulation of dnmt3a Attenuates the Warburg Effect, Proliferation, and Invasion via Promoting the Inhibition of miR-603 on HK2 in ovarian cancer.
Lu J; Zhen S; Tuo X; Chang S; Yang X; Zhou Y; Chen W; Zhao L; Li X
Technol Cancer Res Treat; 2022; 21():15330338221110668. PubMed ID: 35770296
[No Abstract] [Full Text] [Related]
7. Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With ovarian cancer.
Weber-Lassalle K; Ernst C; Reuss A; Möllenhoff K; Baumann K; Jackisch C; Hauke J; Dietrich D; Borde J; Park-Simon TW; Hanker L; Prieske K; Schmidt S; Weber-Lassalle N; Pohl-Rescigno E; Kommoss S; Marmé F; Heitz F; Stingl JC; Schmutzler RK; Harter P; Hahnen E
J Natl Cancer Inst; 2022 Apr; 114(4):565-570. PubMed ID: 34963005
[TBL] [Abstract] [Full Text] [Related]
8. [Ginsenoside 20(S)-Rg3 upregulates tumor suppressor VHL gene expression by suppressing dnmt3a-mediated promoter methylation in ovarian cancer cells].
Wang L; Han X; Zheng X; Zhou Y; Hou H; Chen W; Li X; Zhao L
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Jan; 41(1):100-106. PubMed ID: 33509760
[TBL] [Abstract] [Full Text] [Related]
9. BRCA Methylation Testing Identifies a Subset of ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
[TBL] [Abstract] [Full Text] [Related]
10. MassArray analysis of genomic susceptibility variants in ovarian cancer.
Verma S; Sharma I; Sharma V; Bhat A; Shah R; Bhat GR; Sharma B; Bakshi D; Nagpal A; Wakhloo A; Bhat A; Kumar R
Sci Rep; 2020 Dec; 10(1):21101. PubMed ID: 33273524
[TBL] [Abstract] [Full Text] [Related]
11.
Gospodinova ZI; Zupkó I; Bózsity N; Manova VI; Georgieva MS; Todinova SJ; Taneva SG; Ocsovszki I; Krasteva ME
Z Naturforsch C J Biosci; 2021 Mar; 76(3-4):129-140. PubMed ID: 32975208
[TBL] [Abstract] [Full Text] [Related]
12. Ginsenoside 20(S)-Rg3 upregulates HIF-1α-targeting miR-519a-5p to inhibit the Warburg effect in ovarian cancer cells.
Lu J; Chen H; He F; You Y; Feng Z; Chen W; Li X; Zhao L
Clin Exp Pharmacol Physiol; 2020 Aug; 47(8):1455-1463. PubMed ID: 32271958
[TBL] [Abstract] [Full Text] [Related]
13. Regulation of carcinogenesis and modulation through Wnt/β-catenin signaling by curcumin in an ovarian cancer cell line.
Yen HY; Tsao CW; Lin YW; Kuo CC; Tsao CH; Liu CY
Sci Rep; 2019 Nov; 9(1):17267. PubMed ID: 31754130
[TBL] [Abstract] [Full Text] [Related]
14. miR-145 promotes miR-133b expression through c-myc and dnmt3a-mediated methylation in ovarian cancer cells.
Li J; Zhang S; Zou Y; Wu L; Pei M; Jiang Y
J Cell Physiol; 2020 May; 235(5):4291-4301. PubMed ID: 31612498
[TBL] [Abstract] [Full Text] [Related]
15. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.
Nteliopoulos G; Bazeos A; Claudiani S; Gerrard G; Curry E; Szydlo R; Alikian M; Foong HE; Nikolakopoulou Z; Loaiza S; Khorashad JS; Milojkovic D; Perrotti D; Gale RP; Foroni L; Apperley JF
Haematologica; 2019 Dec; 104(12):2400-2409. PubMed ID: 31073075
[TBL] [Abstract] [Full Text] [Related]
16. Effects of ginsenoside Rg3 on epigenetic modification in ovarian cancer cells.
Zhao L; Shou H; Chen L; Gao W; Fang C; Zhang P
Oncol Rep; 2019 Jun; 41(6):3209-3218. PubMed ID: 31002353
[TBL] [Abstract] [Full Text] [Related]
17. PGK1 facilities cisplatin chemoresistance by triggering HSP90/ERK pathway mediated DNA repair and methylation in endometrial endometrioid adenocarcinoma.
Zhou JW; Tang JJ; Sun W; Wang H
Mol Med; 2019 Mar; 25(1):11. PubMed ID: 30925862
[TBL] [Abstract] [Full Text] [Related]
18. How we use hospice: Hospice enrollment patterns and costs in elderly ovarian cancer patients.
Taylor JS; Zhang N; Rajan SS; Chavez-MacGregor M; Zhao H; Niu J; Meyer LA; Ramondetta LM; Bodurka DC; Lairson DR; Giordano SH
Gynecol Oncol; 2019 Mar; 152(3):452-458. PubMed ID: 30876488
[TBL] [Abstract] [Full Text] [Related]
19. dnmt3a/3B overexpression might be correlated with poor patient survival, hypermethylation and low expression of ESR1/PGR in endometrioid carcinoma: an analysis of The cancer Genome Atlas.
He D; Wang X; Zhang Y; Zhao J; Han R; Dong Y
Chin Med J (Engl); 2019 Jan; 132(2):161-170. PubMed ID: 30614867
[TBL] [Abstract] [Full Text] [Related]
20. MAGEA1 inhibits the expression of BORIS via increased promoter methylation.
Zhao J; Wang Y; Liang Q; Xu Y; Sang J
J Cell Sci; 2019 Jan; 132(1):. PubMed ID: 30498011
[TBL] [Abstract] [Full Text] [Related]
[Next]
